Updated dailyPubMed-sourced · Research, not medical advice
PeptideResearchNewsScience · Studies · Signal
← Peptide GuidesMetabolic & GLP-1

Cagrilintide

Also known as: Cagrilintide · amylin analog

An investigational long-acting amylin analog studied for weight management.

⚕️ Educational reference only — not medical advice. Many peptides are not approved for human use and are sold for research purposes only. Always consult a qualified healthcare professional.
At a glance
StatusInvestigational / clinical development
FDA approvedYes, for approved indications
Human evidenceEmerging
Last evidence reviewOctober 2026
Human evidence
Preclinical evidence
Long-term safety evidence

Human data exists or is emerging, but regulatory approval and long-term safety remain unresolved.

Overview

Cagrilintide is a long-acting amylin analog in clinical development for weight management, often studied in combination with semaglutide (the combination is referred to as CagriSema).

How It's Thought to Work

Amylin is a hormone co-secreted with insulin that promotes satiety and slows gastric emptying; cagrilintide is designed to mimic those effects with a long duration of action.

What the Research Says

Supported by ongoing human clinical trials, including combination studies with semaglutide. It is not yet approved.

Key studies to start with

PubMed

Continued CagriSema treatment preserves weight loss by reducing energy intake and maintaining energy expenditure in rats

Molecular metabolism · 2026 Oct 28

PubMed

Efficacy and Safety of CagriSema in Type 2 Diabetes: A Dose- and Comparator-Specific Systematic Review and Bayesian Meta-Analysis

Diabetes, obesity & metabolism · 2026 Oct 27

PubMed

CagriSema versus Semaglutide 2.4 mg monotherapy for weight management in adults with overweight or obesity, with or without type 2 diabetes: a systematic review, meta-analysis, and trial sequential analysis

Frontiers in endocrinology · 2026

Regulatory & Legal Status

Investigational — not FDA-approved. Any consumer 'research chemical' version is unapproved and unregulated.

Safety Considerations

Long-term human safety is still being established in trials. Not available as an approved medicine. Consult a clinician.

Frequently Asked Questions

What is Cagrilintide?

Cagrilintide is a long-acting amylin analog in clinical development for weight management, often studied in combination with semaglutide (the combination is referred to as CagriSema).

How does Cagrilintide work?

Amylin is a hormone co-secreted with insulin that promotes satiety and slows gastric emptying; cagrilintide is designed to mimic those effects with a long duration of action.

What does the research say about Cagrilintide?

Supported by ongoing human clinical trials, including combination studies with semaglutide. It is not yet approved.

Is Cagrilintide FDA-approved or legal to buy?

Investigational — not FDA-approved. Any consumer 'research chemical' version is unapproved and unregulated.

Is Cagrilintide safe? What are the risks?

Long-term human safety is still being established in trials. Not available as an approved medicine. Consult a clinician.

On the Podcasts

  • Trick or Treatment? A Halloween Guide to AOD, Cagrilintide, and Weight-Loss Peptides 🎃

Want the latest on Cagrilintide as it publishes?

Browse ResearchAll Peptide Guides